1
|
Wang L, Wu YL, Lu S, Deng L, Ahn MJ, Hsu FM, Iscoe N, Hossain A, Puri T, Zhang P, Orlando M. An East Asian subgroup analysis of PROCLAIM, a phase III trial of pemetrexed and cisplatin or etoposide and cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small cell lung cancer. Asia Pac J Clin Oncol 2016; 12:380-387. [PMID: 27312514 DOI: 10.1111/ajco.12513] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2016] [Revised: 03/07/2016] [Accepted: 04/13/2016] [Indexed: 12/28/2022]
Affiliation(s)
- Luhua Wang
- Department of Radiotherapy; Cancer Hospital; Chinese Academy of Medical Sciences; Peking Union Medical College; Beijing China
| | - Yi-Long Wu
- Guangdong Lung Cancer Institute; Guangdong General Hospital and Guangdong Academy of Medical Sciences; Guangzhou China
| | - Shun Lu
- Lung Cancer Center; Shanghai Chest Hospital; Shanghai Jiao Tong University; Shanghai China
| | - Lei Deng
- Department of Radiotherapy; Cancer Hospital; Chinese Academy of Medical Sciences; Peking Union Medical College; Beijing China
| | - Myung-Ju Ahn
- Samsung Medical Center; Gangnam-Gu Seoul The Republic of Korea
| | - Feng-Ming Hsu
- Division of Radiation Oncology; Department of Oncology; National Taiwan University Hospital; Taipei City Taiwan
| | - Neill Iscoe
- Global Medical Affairs; Eli Lilly Canada Inc; Toronto Canada
- Eli Lilly and Company; Indianapolis Indiana USA
| | - Anwar Hossain
- Statistical Sciences; Eli Lilly and Company; Indianapolis Indiana USA
| | - Tarun Puri
- Emerging Markets; Eli Lilly and Company; Gurgaon Haryana India
| | - Pinghai Zhang
- Oncology; Lilly China Drug Development and Medical Affairs Center; Eli Lilly and Company; Shanghai China
| | - Mauro Orlando
- Emerging Markets; Eli Lilly and Company; Buenos Aires Argentina
| |
Collapse
|
2
|
Durm G, Hanna N. An update on current standards and clinical trials in systemic therapy for stage III NSCLC. Lung Cancer Manag 2015. [DOI: 10.2217/lmt.15.29] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Despite a number of recent breakthroughs in the treatment of metastatic NSCLC, the management of patients with stage III disease remains a challenge. The standard of care remains concurrent chemoradiation, and though a number of treatment strategies have been studied, no novel approach has clearly shown a consistent benefit. Future studies will focus on treatment with targeted therapies in selected patient populations and the use of novel immunotherapeutic strategies, such as checkpoint inhibitors, as consolidation therapy. This paper will review ongoing efforts to utilize innovative approaches to improve outcomes in this potentially curable subset of patients.
Collapse
Affiliation(s)
- Greg Durm
- Indiana University Simon Cancer Center, Indianapolis, IN 46202, USA
| | - Nasser Hanna
- Indiana University Simon Cancer Center, Indianapolis, IN 46202, USA
| |
Collapse
|